Recipient Daniel Timms can now
stand and walk again using his ReWalk System
LONDON and YOKNEAM,
Israel, Dec. 22, 2016 /PRNewswire/ -- ReWalk Robotics
Ltd. (Nasdaq: RWLK) ("ReWalk"), the leading global exoskeleton
developer and manufacturer, announced today the donation of a
ReWalk Personal 6.0 System to Daniel
Timms, who sustained a spinal cord injury (SCI) in 2012 in a
parachuting accident. Thanks to a number of generous donors,
Walkabout Foundation, a London-based not-for-profit organization that
donates wheelchairs to disadvantaged individuals worldwide and
supports critical research in paralysis, was able to provide the
device for Mr. Timms.
Daniel, a 36-year old chartered accountant and director of
finance in the healthcare industry, was injured in July 2012 on a parachuting trip. The
accident left Timms with a T-12 spinal cord injury, paralyzed from
the waist down. After being introduced to the ReWalk
exoskeleton, he began training on the 6.0 Personal System model in
2016. Having completed the necessary training, Timms recently
received his donated system from Walkabout Foundation.
"I am grateful to Walkabout Foundation for this generous
donation, and for all they do to support the SCI community," Timms
said. "It is life changing to have my own ReWalk system, and
be able to use it to stand, walk and go about my day like I
normally would before I was paralyzed. I hope my story will
inspire others to try exoskeleton devices as well," he added.
"This donation marks the next step in the support of pioneering
research that we aim for as an organization," said Carolina Gonzalez-Bunster, co-founder of
Walkabout Foundation.
Isabel Falkenberg, Walkabout
Foundation's CEO, said, "Exoskeleton technology like the ReWalk is
an exciting development in the fields of paralysis research and
rehabilitation. We're so pleased to be a part of a project that is
so cutting-edge, and that compliments other research ventures we
currently support, all of which have shown a series of very
tangible results."
Siblings Luis and Carolina
Gonzalez-Bunster established Walkabout Foundation in August
2009. Luis (who suffered a spinal cord injury in a car
accident when he was 18 years old) and his sister were inspired to
start Walkabout Foundation based on Luis' own accessibility
challenges in his local community. They began the charity to
promote awareness of paralysis and disabilities. Since its
inception, Walkabout Foundation has provided more than 10,000
wheelchairs worldwide, spanning 20 countries, in addition to
providing nearly £1 million to groundbreaking research dedicated to
finding a cure for paralysis.
"This donation represents an important partnership of
organizations working to change the lives of the SCI community,"
said ReWalk CEO Larry
Jasinski. "We are thrilled to see Daniel take home his
ReWalk system, and are inspired by the global impact Walkabout
Foundation has on those individuals with SCI in need of access to
cutting edge technology. By working together, we can advance
the goals of innovation for everyone in this community."
ReWalk Robotics Personal 6.0 is a wearable robotic exoskeleton
that provides powered hip and knee motion to enable individuals
with spinal cord injury to stand upright and walk. ReWalk is the
first exoskeleton system to receive FDA clearance for use in the
home as well as in the rehabilitation setting. ReWalk
received FDA clearance in June 2014,
and a CE mark in June 2010.
About Walkabout Foundation
Walkabout Foundation is a
non-profit organization with a mission of restoring dignity,
freedom and independence by providing wheelchairs and
rehabilitation in the developing world and funding research to find
a cure for paralysis. Since it was co-founded by siblings
Luis and Carolina Gonzalez-Bunster
in 2009, Walkabout Foundation has distributed over 10,000
wheelchairs in 20 countries, impacting the lives of 30,000 people,
and has donated nearly £1 million to cutting-edge research. For
more information about Walkabout Foundation, please visit
www.walkaboutfoundation.org.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd.
develops, manufactures and markets wearable robotic exoskeletons
for individuals with spinal cord injury. Our mission is to
fundamentally change the quality of life for individuals with lower
limb disability through the creation and development of market
leading robotic technologies. Founded in 2001, ReWalk has
headquarters in the U.S., Israel
and Germany. For more information
on the ReWalk systems, please
visit http://www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in
Israel.
Forward-Looking Statements
In addition to historical
information, this press release contains forward-looking statements
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995, Section 27A of the U.S. Securities Act of 1933, and
Section 21E of the U.S. Securities Exchange Act of 1934. Such
forward-looking statements may include projections regarding
ReWalk's future performance and, in some cases, may be identified
by words like "anticipate," "assume," "believe," "continue,"
"could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "future," "will," "should,"
"would," "seek" and similar terms or phrases. The forward-looking
statements contained in this press release are based on
management's current expectations, which are subject to
uncertainty, risks and changes in circumstances that are difficult
to predict and many of which are outside of ReWalk's control.
Important factors that could cause ReWalk's actual results to
differ materially from those indicated in the forward-looking
statements include, among others: ReWalk's expectations regarding
future growth, including its ability to increase sales in its
existing geographic markets and to expand to new markets; ReWalk's
ability to maintain and grow its reputation and to achieve and
maintain market acceptance of its products; ReWalk's ability to
achieve reimbursement from third-party payors for its products;
ReWalk's expectations as to its clinical research program and
clinical results; ReWalk's expectations as to the results of, and
the Food and Drug Administration's potential regulatory actions
with respect to, ReWalk's mandatory post-market 522 surveillance
study; ReWalk's ability to repay its secured indebtedness; ReWalk's
ability to improve its products and develop new products; ReWalk's
ability to maintain adequate protection of its intellectual
property and to avoid violation of the intellectual property rights
of others; ReWalk's ability to gain and maintain regulatory
approvals; ReWalk's ability to secure capital from its
at-the-market equity distribution program based on the price range
of its ordinary shares and conditions in the financial markets;
ReWalk's ability to maintain relationships with existing customers
and develop relationships with new customers; and other factors
discussed under the heading "Risk Factors" in ReWalk's Annual
Report on Form 10-K for the year ended December 31, 2015 filed with the U.S. Securities
and Exchange Commission and other documents subsequently filed with
or furnished to the U.S. Securities and Exchange Commission. Any
forward-looking statement made in this press release speaks only as
of the date hereof. Factors or events that could cause ReWalk's
actual results to differ from the statements contained herein may
emerge from time to time, and it is not possible for ReWalk to
predict all of them. Except as required by law, ReWalk undertakes
no obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or
otherwise.
LOGO: http://photos.prnewswire.com/prnh/20150713/235995LOGO